Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlexanox for Glucose and Lipid Abnormalities in Obese Type 2 Diabetics
NCT01842282Phase 2Terminated
- Sponsor
- University of Michigan
- Start
- Jul 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amlexanox in type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), obesity, sponsored by University of Michigan. Started Jul 2013; status: terminated.
02
Drugs
amlexanox
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)obesity
Beyond the preview
Go deeper on NCT01842282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01842282.